Month: July 2026

CHARLOTTE, N.C., July 01, 2026 (GLOBE NEWSWIRE) — NN, Inc. (“NN” or the “Company”) (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies with six sigma quality, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of $75.0 million before deducting placement agent fees and offering expenses. The PIPE is expected to close on or about July 2, 2026, subject to the satisfaction of customary closing conditions.

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, NN will issue an aggregate of 24,509,804 shares of common stock at a price of $3.06 per share.

The Company intends to use the net proceeds from the PIPE for working capital and general corporate purposes, which may include actions designed to optimize NN’s balance sheet.

Harold Bevis, President and CEO of NN, stated, “We are excited to bring new investors into the stock who are committed to our business plan. The capital from this offering also provides us flexibility to take actions to strengthen our balance sheet, which we believe will provide long-term benefits to our investors.”

Craig-Hallum Capital Group LLC acted as the sole placement agent for the PIPE. Cooley LLP served as counsel to NN for the PIPE and Faegre Drinker Biddle & Reath served as counsel to the placement agent.

The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, NN and the investors named therein entered into a registration rights agreement pursuant to which NN has agreed to file a registration statement with the U.S. Securities and Exchange Commission (“SEC”) registering the resale of the shares of common stock.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NN

NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and China. For more information about the Company and its products, please visit www.nninc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the timing and completion of the PIPE, the use of the net proceeds from the PIPE, including any potential actions designed to optimize the Company’s balance sheet and any potential long-term benefits to our investors of such actions, and other statements that are not historical facts. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project,” “achieve,” “growth,” “enable,” “improve,” or the negative of these terms, and similar words, phrases or expressions that convey uncertainty of future events or outcomes. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, matters related to the completion of the PIPE and related transactions, including the need to satisfy the closing conditions therefor. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the SEC. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor Relations:
Joseph Caminiti
[email protected]
312-445-2870 

The deal winter is over. After years of stalled negotiations and a near-frozen M&A market, 2026 has arrived with a thaw that is reshaping the opportunity landscape for investors at every level. U.S. merger and acquisition transactions over $100 million are up 25% by volume and 43% by value compared to the same period last year, and the companies drawing the most aggressive attention are not the household names. They are the smaller, leaner innovators that large strategics and private equity firms have been quietly circling.

The catalyst is a convergence of factors that rarely align at once. Nearly $440 billion in private equity dry powder is specifically earmarked for smaller enterprises. Stabilizing interest rates following years of Fed tightening have narrowed the valuation gap that froze so many deals. And a shift in antitrust enforcement, with the FTC under new leadership focusing scrutiny on mega-mergers rather than smaller bolt-on acquisitions, has cleared a regulatory runway that simply did not exist two years ago.

Biopharma Is Driving the Biggest Wave

Nowhere is the acquisition appetite more pronounced than in life sciences. IQVIA forecasts aggregate biopharma M&A deal value of $140 billion to $160 billion for full-year 2026, with upside potential of an additional $20 to $30 billion. Oncology is the primary target area, accounting for roughly 39% of total transaction volume. Large pharmaceutical companies facing patent cliffs on blockbuster drugs are finding it more capital-efficient to acquire late-stage small-cap biotechs than to fund the same pipeline development in-house.

Small-cap developers in oncology, rare disease, and high-growth therapeutic categories like GLP-1 drugs, where the market opportunity is projected to reach $100 billion by 2030, are drawing the most serious acquirer interest. Companies like Cardiff Oncology and MAIA Biotechnology are among the smaller-cap names building programs in therapeutic areas where large-cap acquirers are actively hunting for pipeline replenishment.

How Deal Structures Have Evolved

It is not just volume that has shifted. The mechanics of how deals get done have evolved as well. Today’s acquirers are structuring transactions around free cash flow multiples and sustainable margins, rather than the growth-at-any-cost narratives that defined the SPAC era. Contingent value rights (CVRs) are increasingly common, allowing buyers and sellers to share risk on clinical or commercial milestones, which makes smaller biotech deals executable even under significant uncertainty.

This shift favors companies with differentiated science and disciplined financials over those with only a compelling story. For acquirers, the logic is clear: buying validated late-stage assets is cheaper than building them internally, particularly in a higher-rate environment.

What This Means for Small and Microcap Investors

For investors focused on small and microcap companies, this is among the most favorable M&A backdrops in recent memory. Acquisition premiums in small-cap biotech and specialty pharma deals have historically ranged from 50% to over 100% above pre-announcement prices. The profiles that attract strategic buyers, differentiated pipelines, clean balance sheets, and validated mechanisms of action, are concentrated precisely in the sub-$2 billion market cap space where most individual investors are underexposed.

The opportunity is not in chasing deal rumors. It is in understanding the strategic logic driving large-cap acquirers: they need what smaller companies have built, and in 2026, they are increasingly willing to pay for it.